Meeting
2012 ASCO Annual Meeting
Adjuvant dendritic cell (DC)-based vaccine therapy of melanoma patients.
Authors
Natalia N. Petenko
N. N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia
Natalia N. Petenko , Irina N. Mikhaylova , George Z. Chkadua , Anatoly Y. Baryshnikov , Lev V. Demidov
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Immunotherapy
Track
Developmental Therapeutics
Sub Track
Immunotherapy and Biologic Therapy
Clinical Trial Registration Number
NA
Citation
J Clin Oncol 30, 2012 (suppl; abstr 2524)
DOI
10.1200/jco.2012.30.15_suppl.2524
Abstract #
2524
Poster Bd #
12
Abstract Disclosures
Similar Posters
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
A phase I/IIa clinical trial investigating the therapeutic cancer vaccine UV1 in combination with ipilimumab in patients with malignant melanoma: Four-year survival update.
First Author: Espen Basmo Ellingsen
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
A prospective, randomized, blinded, placebo-controlled, phase IIb trial of an autologous tumor lysate + yeast cell wall particles (YCWP) + dendritic cells (DC) vaccine vs unloaded YCWP + DC and embedded phase I/IIa trial with tumor lysate particle only (TLPO) vaccine in stage III and stage IV (resected) melanoma to prevent recurrence.
First Author: John W Myers
Poster
2016 ASCO Annual Meeting
Retrospective cohort analysis of adjuvant NY-ESO-1 vaccines in stage III melanoma.
First Author: Michael William Lattanzi
Poster
2016 ASCO Annual Meeting
A Phase II Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand.
First Author: Nina Bhardwaj